Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study

Interventions to Improve Oral Chemotherapy Safety and Quality

(2018) Jessica A. Zerillo et al.   JAMA Oncology

A systematic checklist approach to immunosuppression risk management: An audit of practice at two clinical neuroimmunology centers

(2017) Amelia M. Mori et al.   JOURNAL OF NEUROIMMUNOLOGY

A multiple-scenario assessment of the effect of a continuous-care, guideline-based decision support system on clinicians’ compliance to clinical guidelines

(2015) Erez Shalom et al.   INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS

HIV Laboratory Monitoring Reliably Identifies Persons Engaged in Care

(2015) Bonnie B. Dean et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

(2014) O. Tuohy et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Efficacy of a Clinical Decision-Support System in an HIV Practice

(2013) Gregory K. Robbins et al.   ANNALS OF INTERNAL MEDICINE

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Alemtuzumab more effective than interferon  -1a at 5-year follow-up of CAMMS223 Clinical Trial

(2012) A. J. Coles et al.   NEUROLOGY

Managing the risks of immunosuppression

(2011) D Sean Riminton et al.   CURRENT OPINION IN NEUROLOGY

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE